Tobacco Smoking and Risk for Pulmonary Fibrosis: A Prospective Cohort Study From the UK Biobank
- PMID: 33905677
- DOI: 10.1016/j.chest.2021.04.035
Tobacco Smoking and Risk for Pulmonary Fibrosis: A Prospective Cohort Study From the UK Biobank
Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease of unknown origin. A limited number of small studies show an effect of tobacco smoking on risk of IPF, but second-hand smoking has not been examined.
Research question: Are smoking-related exposures associated with risk of IPF and does interaction between them exist?
Study design and methods: We designed a prospective cohort study using UK Biobank data, including 437,453 nonrelated men and women of White ethnic background (40-69 years of age at baseline). We assessed the effect of tobacco smoking-related exposures on risk for IPF using Cox regression adjusted for age, sex, Townsend deprivation index, and home area population density. We also examined potential additive and multiplicative interaction between these exposures. Multiple imputation with chained equations was used to address missing data.
Results: We identified 802 incident IPF cases. We showed an association between smoking status (hazard ratio [HR], 2.12; 95% CI, 1.81-2.47), and maternal smoking (HR, 1.38; 95% CI, 1.18-1.62) with risk of IPF. In ever smokers, a dose-response relationship was observed between pack-years of smoking and risk of IPF (HR per 1-pack-year increase, 1.013; 95% CI, 1.009-1.016). Furthermore, an additive and multiplicative interaction was observed between maternal smoking and smoking status, with a relative excess risk due to interaction of 1.00 (95% CI, 0.45-1.54) and a ratio of HRs of 1.50 (95% CI, 1.05-2.14).
Interpretation: Active and maternal tobacco smoking have an independent detrimental effect on risk of IPF and work synergistically. Also, intensity of smoking presents a dose-response association with IPF, strengthening the hypothesis for a potentially causal association.
Keywords: UK Biobank; cohort study; idiopathic pulmonary fibrosis; interaction; smoking.
Copyright © 2021. Published by Elsevier Inc.
Similar articles
-
Early-Life Exposure to Tobacco Smoke and the Risk of Idiopathic Pulmonary Fibrosis: A Population-Based Cohort Study.Ann Am Thorac Soc. 2025 Jun;22(6):887-896. doi: 10.1513/AnnalsATS.202409-906OC. Ann Am Thorac Soc. 2025. PMID: 39879538
-
Physical activity and idiopathic pulmonary fibrosis: A prospective cohort study in UK Biobank and Mendelian randomization analyses.Respir Med Res. 2024 Nov;86:101141. doi: 10.1016/j.resmer.2024.101141. Epub 2024 Oct 5. Respir Med Res. 2024. PMID: 39413579
-
Impact of smoking on the development of idiopathic pulmonary fibrosis: results from a nationwide population-based cohort study.Thorax. 2022 May;77(5):470-476. doi: 10.1136/thoraxjnl-2020-215386. Epub 2021 Sep 30. Thorax. 2022. PMID: 34593614
-
Work-related interstitial lung disease: what is the true burden?Int J Tuberc Lung Dis. 2022 Nov 1;26(11):1001-1005. doi: 10.5588/ijtld.22.0212. Int J Tuberc Lung Dis. 2022. PMID: 36281049 Review.
-
Idiopathic pulmonary fibrosis: diagnosis and epidemiology.Clin Chest Med. 2012 Mar;33(1):41-50. doi: 10.1016/j.ccm.2011.12.001. Clin Chest Med. 2012. PMID: 22365244 Review.
Cited by
-
Effect of Antifibrotic Use on Mortality in Patients with Idiopathic Pulmonary Fibrosis.Ann Am Thorac Soc. 2024 Oct;21(10):1407-1415. doi: 10.1513/AnnalsATS.202312-1054OC. Ann Am Thorac Soc. 2024. PMID: 39012168
-
Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies.Front Pharmacol. 2023 Aug 7;14:1205948. doi: 10.3389/fphar.2023.1205948. eCollection 2023. Front Pharmacol. 2023. PMID: 37608885 Free PMC article. Review.
-
Alleviation of pulmonary fibrosis by the dual PPAR agonist saroglitazar and breast milk mesenchymal stem cells via modulating TGFß/SMAD pathway.Naunyn Schmiedebergs Arch Pharmacol. 2024 Aug;397(8):5953-5974. doi: 10.1007/s00210-024-03004-y. Epub 2024 Feb 20. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38376539 Free PMC article.
-
Effect of pirfenidone on pulmonary fibrosis in acute lung injury via the regulation of the miR-34a-5p/TGF-β1/SMAD pathway.J Thorac Dis. 2025 Jun 30;17(6):4238-4248. doi: 10.21037/jtd-2025-829. Epub 2025 Jun 18. J Thorac Dis. 2025. PMID: 40688289 Free PMC article.
-
Highlights on Future Treatments of IPF: Clues and Pitfalls.Int J Mol Sci. 2024 Aug 1;25(15):8392. doi: 10.3390/ijms25158392. Int J Mol Sci. 2024. PMID: 39125962 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical